These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8082513)

  • 1. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.
    Grimbert S; Pessayre D; Degott C; Benhamou JP
    Dig Dis Sci; 1994 Sep; 39(9):2032-3. PubMed ID: 8082513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute cholestatic hepatitis during simvastatin administration.
    Ballaré M; Campanini M; Catania E; Bordin G; Zaccala G; Monteverde A
    Recenti Prog Med; 1991 Apr; 82(4):233-5. PubMed ID: 1857844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatitis associated with treatment with lovastatin. Presentation of 2 cases].
    Bruguera M; Joya P; Rodés J
    Gastroenterol Hepatol; 1998 Mar; 21(3):127-8. PubMed ID: 9607293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lovastatin-induced acute cholestatic hepatitis].
    Huchzermeyer H; Münzenmaier R
    Dtsch Med Wochenschr; 1995 Feb; 120(8):252-6. PubMed ID: 7867482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lovastatin-induced hepatitis.
    Raveh D; Arnon R; Israeli A; Eisenberg S
    Isr J Med Sci; 1992 Feb; 28(2):101-2. PubMed ID: 1559791
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy.
    Stein CA; Goel S; Ghavamian R
    Invest New Drugs; 2007 Jun; 25(3):277-8. PubMed ID: 17216557
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute cholestatic hepatitis associated with pravastatin.
    Hartleb M; Rymarczyk G; Januszewski K
    Am J Gastroenterol; 1999 May; 94(5):1388-90. PubMed ID: 10235223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Worldwide experience with simvastatin/lovastatin.
    Walker JF
    Eur Heart J; 1992 Jul; 13 Suppl B():21-2. PubMed ID: 1644097
    [No Abstract]   [Full Text] [Related]  

  • 10. [Toxic liver damage caused by HMG-CoA reductase inhibitor].
    Heuer T; Gerards H; Pauw M; Gabbert HE; Reis HE
    Med Klin (Munich); 2000 Nov; 95(11):642-4. PubMed ID: 11143546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Simvastatin-induced hepatitis].
    Roblin X; Becot F; Piquemal A; Baziz A
    Gastroenterol Clin Biol; 1992; 16(1):101. PubMed ID: 1537472
    [No Abstract]   [Full Text] [Related]  

  • 12. Defining patient risks from expanded preventive therapies.
    Tolman KG
    Am J Cardiol; 2000 Jun; 85(12A):15E-9E. PubMed ID: 10858489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatitis due to lovastatin].
    Gavilán Carrasco JC; Bermúdez Recio F; Salgado Ordóñez F; González Santos P
    Med Clin (Barc); 1996 Oct; 107(14):557-8. PubMed ID: 8999220
    [No Abstract]   [Full Text] [Related]  

  • 14. Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy.
    Chu PH; Chen WJ; Chiang CW; Lee YS
    Jpn Heart J; 1997 Jul; 38(4):541-5. PubMed ID: 9350151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all.
    Grieco A; Miele L; Pompili M; Biolato M; Vecchio FM; Grattagliano I; Gasbarrini G
    J Hepatol; 2009 Jun; 50(6):1273-7. PubMed ID: 19398239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors.
    Ballarè M; Campanini M; Airoldi G; Zaccala G; Bertoncelli MC; Cornaglia G; Porzio M; Monteverde A
    Minerva Gastroenterol Dietol; 1992; 38(1):41-4. PubMed ID: 1520752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cholestatic jaundice during lovastatin medication].
    Spreckelsen U; Kirchhoff R; Haacke H
    Dtsch Med Wochenschr; 1991 May; 116(19):739-40. PubMed ID: 2026107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lovastatin for hypercholesterolemia.
    Med Lett Drugs Ther; 1987 Nov; 29(752):99-101. PubMed ID: 3312981
    [No Abstract]   [Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
    Weber C; Erl W; Weber KS; Weber PC
    J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.